Welcome to Our Group

This research group is a collective of highly accomplished professionals united by their shared commitment to advancing nanotechnology, drug delivery systems, and biomedical applications. The team’s expertise spans various fields including nanobiotechnology, pharmaceutics, chemical biology, and material sciences, with a primary focus on innovative therapeutic solutions. Key members of the group include Dr. Walhan Alshaer, a distinguished researcher at the University of Jordan, specializing in ligand-guided nanomedicines for targeted drug delivery, and Prof. Alaaldin M. Alkilany, a leading expert in nanomaterials for drug delivery at Qatar University, recognized as one of the top 2% of scientists globally. Additionally, Dr. Ahmad Telfah, with his background in physical chemistry and nanotechnology, contributes through his expertise in computational modeling and high-resolution analytical techniques. Prof. Sharif Abdelghany, a Professor in the Department of Pharmaceutics and Pharmaceutical Technology at the University of Jordan since 2012, brings significant expertise in drug delivery and biomaterials. He has published extensively on microneedles and nanoparticles for drug delivery, focusing on safe, pain-free delivery systems for diseases like cancer, diabetes, and infectious diseases. Dr. Khaled Khraisat, the Founder and CEO of JAIP (Academia Industry Platform Co.Ltd), has 27 years of experience in business development within the life sciences industry. He brings a wealth of knowledge in strategic planning, business modeling, and industrial project management, along with extensive experience in scaling up businesses in pharmaceutical, cosmetic, and food industries.
The group’s work centers around developing cutting-edge nanomedicines, including microneedle systems, ligand-guided nanocarriers, and nanoparticles, aimed at achieving targeted and efficient drug delivery for complex diseases such as cancer, diabetes, and infectious diseases. The research explores high-resolution analytical techniques, computational simulations, and nanomaterial development to improve the precision, safety, and efficacy of therapeutic systems.
The research group’s contributions extend beyond drug delivery. Their work in nucleic acid-based therapeutics, including aptamers and siRNA, represents cutting-edge approaches in targeting genetic material to treat diseases. Additionally, the team is focused on tackling cancer resistance mechanisms, studying molecular pharmacology to identify drugs that overcome treatment resistance, and exploring the therapeutic potential of mesenchymal stem cells (MSCs) in cancer treatment.
Another significant aspect of their work includes the development of polymeric microneedles for painless and effective drug delivery, an innovative technology poised to enhance patient compliance, especially for vaccine and insulin delivery. The group also focuses on the synthesis and characterization of nanoparticles, such as gold, silver, and PLGA nanoparticles, for targeted drug delivery and biomedical applications.
Members of this team have been internationally recognized for their contributions, including receiving awards such as the Ali Manko Award for Outstanding Researcher, prestigious fellowships, and recognition in Stanford University's list of top scientists globally. Their integration of multidisciplinary approaches continues to make significant strides in healthcare innovation, with research that bridges the gap between academia and industry.